Therapeutic area intelligence for Hereditary Angioedema with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Astria Therapeutics →

Assets

Octapharma →

Phase →

Recent signals(2)

CompetitiveJuly 1, 2026

Phase 3 Trial of C1 Esterase Inhibitor for Acute Hereditary Angioedema by Octapharma

Octapharma is conducting a phase 3 trial of C1 esterase inhibitor concentrate for treating acute hereditary angioedema.

CompetitiveJuly 1, 2026

Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics

Astria Therapeutics has initiated Phase 3 trial for navenibart in patients with hereditary angioedema.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.